STRATHEP develops and validates a multimodal AI model to predict treatment response in advanced hepatocellular carcinoma. By integrating digital pathology and MRI radiomics, the project identifies patients likely to benefit from modern systemic therapies, using the RECIST 1.1 framework as the primary benchmark.
Male or female, age > 18 years
Hepatocellular carcinoma treated with systemic treatment during the disease course
Histological confirmation of HCC within one year of the start of systemic treatment OR the availability of an MRI of the liver within 6 months of the start of systemic treatment
Left-over tissue from previous diagnostic biopsy available
None
Patients with hepatocellular carcinoma (HCC) who received systemic therapy.
Cohort
Prospective
Not listed
Objective Treatment Response Rate (ORR) per RECIST 1.1.
Progression-Free Survival (PFS)
Click on the lead sponsor to view all of their trials.
